Enzymes, such as γ-secretase, are able to cleave and release the extracellular domain of BCMA into the bloodstream as soluble ...

So B-cell maturation antigen is an evolving field where we have three ways of targeting this receptor, including the antibody direct conjugate, as well as the chimeric antigen receptor T-cell ...

A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have already received a proteasome inhibitor, an immunomodulatory agent, and an ...

The use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof ...

The CAR-T-cell therapies targeting B-cell maturation antigen — ciltacabtagene autoleucel and idecabtagene vicleucel — are indicated for multiple myeloma.

Ciltacabtagene autoleucel (cilta-cel) is an FDA-approved anti–B-cell maturation antigen–directed CAR T-cell therapy that is produced by means of lentiviral transduction. In the phase 3 ...

Talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and ...